Login / Signup

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.

Tiansheng WangJeff Y YangJohn B BuseVirginia PateHuilin TangEdward L BarnesRobert S SandlerTil Stürmer
Published in: Diabetes care (2019)
Our population-based cohort study of U.S. adults with diabetes suggests that short-term DPP4i treatment does not increase IBD risk.
Keyphrases
  • type diabetes
  • cardiovascular disease
  • ulcerative colitis
  • glycemic control
  • metabolic syndrome
  • combination therapy
  • adipose tissue
  • skeletal muscle
  • weight loss